Reference is made to the key information relating to the preferential rights issue published by Targovax ASA (the "Company") on 4 November 2021. Please see below for updated key information relating to the preferential rights issue to be carried out by the Company:
Date on which the terms and conditions of the preferential rights issue were announced: 4 November 2021
Last day including right: 25 November 2021
Ex-date: 26 November 2021
Record Date: 29 November 2021
Number of new shares: 101,744,186
Subscription price: NOK 1.72
Ratio preferential rights: Each existing shareholder as of 25 November 2021 (and being registered as such in the Norwegian Central Securities Depository (the VPS) as at the expiry of 29 November 2021 (the record date)) will be granted 1.175114 subscription rights for each share registered as held by the shareholder. The number of subscription rights granted to each existing shareholder will be rounded down to the nearest whole subscription right.
Subscription ratio: 1:1 (number of new shares per preferential right)
Managers: Carnegie AS and DNB Markets, a part of DNB Bank ASA
Will the rights be listed: Yes, under ticker "TRVXT"
ISIN for the preferential rights: NO0011147696
Date of approval: 25 November 2021
Other information: The preferential rights issue is subject to approval by the extraordinary general meeting of Targovax ASA, which will be held on 25 November 2021.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
About Targovax
Activating the patient's immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax aims to unlock greater clinical benefits in cancer patients by deploying its multifunctional platforms to target key immune regulators and oncogenic drivers. Targovax’s focus is to “activate the patient’s immune system to fight cancer”, thus extending and transforming the lives of cancer patients. Targovax’s pipeline aims at different cancer indications, including melanoma, mesothelioma and colorectal cancer. The company’s product candidates are designed to harness the patient’s own immune system to fight the cancer, whilst also delivering a favorable safety and tolerability profile.
Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. On the back of very encouraging clinical data in several indications, both in monotherapy and in multiple combinations, the next development steps for ONCOS-102 will be to further improve responses in melanoma patients resistant to or poorly responsive to current standard of care.